Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc

30 de setembro de 2026 atualizado por: Edwin Posadas, MD

Phase II Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc

This is an open-label, multi-site study of AR Blockade with carotuximab in patients who have progressed on androgen receptor signaling inhibitor (ARSI) therapy. This study will begin with a safety assessment in the first 10 subjects (part 1: Safety Lead-in). If the combination is deemed safe, the trial will proceed to the Phase II stage. The purpose of this study is to compare progression free survival (PFS) between patients receiving AR Blockade and AR Blockade + carotuximab using Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Prostate Cancer Working Group 3. The secondary objectives are to describe adverse events related to the intervention, overall response rate (ORR), proportion of patients resistant to AR blockade that benefit from the addition of carotuximab, and to determine the ORR, radiographic PFS, and biochemical PFS in the overall population.

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Estimado)

116

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

    • California
      • Duarte, California, Estados Unidos, 91010
        • Recrutamento
        • City of Hope
        • Contato:
          • Tanya Dorff, MD
          • Número de telefone: 626-256-4673
          • E-mail: tdorff@coh.org
      • Los Angeles, California, Estados Unidos, 90048
        • Recrutamento
        • Cedars-Sinai Medical Center
        • Subinvestigador:
          • David Hoffman, MD
        • Subinvestigador:
          • Robert Figlin, MD FACP
        • Subinvestigador:
          • Kevin Scher, MD MBA
        • Subinvestigador:
          • Leland Green, MD
        • Subinvestigador:
          • Kristopher Wentzel, MD
        • Subinvestigador:
          • Jun Gong, MD
        • Contato:
        • Contato:
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84112
        • Recrutamento
        • Huntsman Cancer Institute and Hospital
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Macho

Descrição

Inclusion Criteria:

  • History of castration-resistant prostate cancer with rising PSA on a contemporary ARSI (e.g. abiraterone or, enzalutamide, darolutamide). Bicalutamide, nilutamide, and flutamide will not be considered as contemporary ARSIs.

    • PSA rise will be defined as an increase in PSA of 0.2 ng/mL or higher on at least 2 separate occasions greater than 1 week apart while on an ARSI
    • Patient must be surgically castrated or have serum testosterone concentrations much be consistent with castrate levels of testosterone (under 50 ng/dL) while on LHRH analog therapy
    • Patient must have had 1 and can have up to 2 prior AR targeted agents (if patients have had previous enzalutamide, they will be considered only for arm C). therapy with the exception of apalutamide.
    • Patients may not have had previous chemotherapy with the exception of docetaxel administered for castration-sensitive disease.
  • Patients must decline or be ineligible for taxane therapy in the opinion of the treating physician.

  • Have Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1

  • Resolution of adverse events results as described below:

    • If the subject's patient's most recent line of therapy is treatment with abiraterone or enzalutamide, then all adverse events must be resolved to Grade 2 or less
    • If the subject's patient's most recent line of therapy is any other treatment for mCRPC then all Adverse events must be resolved to grade 1 or less, with the exception of fatigue, alopecia and neuropathy (which must resolve to CTCAE grade 2)
  • Adequate organ function

  • All patients must agree to use an adequate method of contraception, in the opinion of the treating investigator, while on protocol treatment and for 3 months after the last dose of protocol treatment (apalutamide/enzalutamide and/or carotuximab)

  • Written informed consent obtained from subject and ability for subject to comply with the requirements of the study

Exclusion Criteria:

  • Non-PSA producing prostate cancers such as small cell prostate cancers or those prostate cancers which exhibit radiographic progression without PSA rise
  • Other prior malignancy requiring active anticancer therapy
  • Prior exposure to carotuximab or any CD105 targeted antibody
  • Any major surgical procedure, in the opinion of the treating physician, within 2 weeks of starting therapy
  • Uncontrolled chronic hypertension defined as sustained systolic pressure (SBP) >150 mmHg or diastolic pressure (DBP) >90 despite optimal therapy
  • Active bleeding or pathologic medical conditions, including but not limited to factor deficiencies, hemophilia, etc., that carries a high bleeding risk
  • Use of thrombolytics within 10 days prior to the first day of carotuximab
  • Known hypersensitivity to Chinese hamster ovary products or other recombinant human, chimeric, or humanized antibodies
  • A known diagnosis of Osler-Weber-Rendu syndrome
  • Ascites or pericardial or pleural effusion requiring external drainage procedures
  • History of untreated brain involvement with cancer, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease. Patients with radiated or resected lesions are permitted, provided the lesions are fully treated and inactive, patients are asymptomatic, and no steroids have been administered for at least 28 days. Imaging for CNS disease will not be required for screening unless there is a history of a neurological finding such as new onset of weakness or numbness that cannot be explained by other medical history.
  • Acute cardiovascular event within the past 6 months. An acute cardiovascular event will be defined as a myocardial infarction, NYHA Class II or worse congestive heart failure, cerebrovascular accident, transient ischemic attack, arterial embolism, pulmonary embolism, percutaneous transluminal coronary angioplasty (PTCA), or CABG.
  • Deep venous thrombosis within the past 6 months, unless the patient is anti-coagulated without the use of warfarin for at least 2 weeks. In this situation, low molecular weight heparin is preferred but clearance should be given by the local PI.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: Enzalutamide Naive - Monotherapy

After progression, subjects will crossover to combination therapy

Standard of care Apalutamide 240 mg / Enzalutamide 160mg administered orally and daily on Days 1-28 of every 28 day cycle

Outros nomes:
  • Enzalutamida
  • Apalutamida
Experimental: Enzalutamide Naive - Combination therapy (Androgen Receptor Blockade + Carotuximab)

Androgen Receptor is Apalutamide 240mg for Lead-In group & Enzalutamide 160mg for all other groups

Standard of care Apalutamide 240 mg / Enzalutamide 160mg administered orally and daily on Days 1-28 of every 28 day cycle

Outros nomes:
  • Enzalutamida
  • Apalutamida

Carotuximab administered intravenously at the following doses:

Cycle 1 Day 1: 3 mg/kg Cycle 1 Day 4: 7 mg/kg Cycle 1 Day 8: 10 mg/kg Cycle 1 Day 15: 10 mg/kg Cycle 1 Day 22: 10 mg/kg Cycle 2 Day 1: 15 mg/kg Cycle 2 Day 15: 15 mg/kg Cycle 3+ Day 1: 15 mg/kg After completion of cycle 2, dosing of carotuximab will continue at a q4 week schedule using the 15 mg/kg dose.

Experimental: Enzalutamide Exposed - Combination therapy (Androgen Receptor Blockade + Carotuximab)

Androgen Receptor is Apalutamide 240mg for Lead-In group & Enzalutamide 160mg for all other groups

Standard of care Apalutamide 240 mg / Enzalutamide 160mg administered orally and daily on Days 1-28 of every 28 day cycle

Outros nomes:
  • Enzalutamida
  • Apalutamida

Carotuximab administered intravenously at the following doses:

Cycle 1 Day 1: 3 mg/kg Cycle 1 Day 4: 7 mg/kg Cycle 1 Day 8: 10 mg/kg Cycle 1 Day 15: 10 mg/kg Cycle 1 Day 22: 10 mg/kg Cycle 2 Day 1: 15 mg/kg Cycle 2 Day 15: 15 mg/kg Cycle 3+ Day 1: 15 mg/kg After completion of cycle 2, dosing of carotuximab will continue at a q4 week schedule using the 15 mg/kg dose.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Progression free survival (rPFS) between patients receiving AR blockade and AR blockade + carotuximab
Prazo: From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.

From the start of study treatment until documented progression, per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Prostate Cancer Working Group 3, or death due to any cause.

From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Incidence of Adverse events (grade 3 or higher) related to carotuximab and AR blockade
Prazo: From start of study treatment through 4 weeks on treatment

Grade 3 or above treatment related adverse events as assessed per NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

From start of study treatment through 4 weeks on treatment
Overall radiographic response rate (ORR) of the combination of AR blockade + carotuximab
Prazo: From the start of combination study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.

Participants of the combination of AR blockade + carotuximab, with confirmed complete response (CR) or partial response (PR) per RECIST v.1.1 and Prostate Cancer Working Group 3

From the start of combination study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
Proportion of patients resistant to AR blockade benefit from the addition of carotuximab
Prazo: From the start of combination therapy study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.

Participants of the monotherapy group that crossover to combination therapy at progression, with confirmed complete response (CR) or partial response (PR) per RECIST v.1.1 and Prostate Cancer Working Group 3

From the start of combination therapy study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
Overall radiographic response rate (ORR) in the overall population
Prazo: From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.

Determined by confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Prostate Cancer Working Group 3

From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
To determine the radiographic progression free survival (rPFS) in the overall population
Prazo: From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.

From the start of study treatment until documented progression, per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Prostate Cancer Working Group 3, or death due to any cause.

From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
To determine the biochemical PFS (by PCWG3) in the overall population
Prazo: From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.

From the start of study treatment until documented progression, per Prostate Cancer Working Group 3, or death due to any cause.

From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Edwin Posadas, MD FACP, Cedars-Sinai Medical Center

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

27 de dezembro de 2023

Conclusão Primária (Estimado)

1 de janeiro de 2028

Conclusão do estudo (Estimado)

1 de janeiro de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

6 de setembro de 2022

Enviado pela primeira vez que atendeu aos critérios de CQ

6 de setembro de 2022

Primeira postagem (Real)

9 de setembro de 2022

Atualizações de registro de estudo

Última Atualização Postada (Real)

5 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

30 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • IIT2021-06-Posadas-AR105

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .